Ovid Therapeutics Inc (OVID) concluded trading on Thursday at a closing price of $0.48, with 24.36 million shares of worth about $11.69 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -36.68% during that period and on July 17, 2025 the price saw a gain of about 22.90%. Currently the company’s common shares owned by public are about 71.11M shares, out of which, 59.51M shares are available for trading.
Stock saw a price change of 14.39% in past 5 days and over the past one month there was a price change of 64.93%. Year-to-date (YTD), OVID shares are showing a performance of -48.93% which decreased to -48.67% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $1.47 during that period. The average intraday trading volume for Ovid Therapeutics Inc shares is 942.95K. The stock is currently trading 33.66% above its 20-day simple moving average (SMA20), while that difference is up 48.86% for SMA50 and it goes to -28.59% lower than SMA200.
Ovid Therapeutics Inc (NASDAQ: OVID) currently have 71.11M outstanding shares and institutions hold larger chunk of about 47.81% of that.
The stock has a current market capitalization of $34.08M and its 3Y-monthly beta is at 0.16. It has posted earnings per share of -$0.35 in the same period. It has Quick Ratio of 4.93 while making debt-to-equity ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OVID, volatility over the week remained 18.48% while standing at 11.85% over the month.
Stock’s fiscal year EPS is expected to drop by -67.46% while it is estimated to decrease by -5.57% in next year.
Coverage by B. Riley Securities stated Ovid Therapeutics Inc (OVID) stock as a Buy in their note to investors on April 30, 2024, suggesting a price target of $9 for the stock. On April 29, 2024, H.C. Wainwright Initiated their recommendations, while on April 05, 2024, Wedbush Initiated their ratings for the stock with a price target of $8. Stock get a Buy rating from BTIG Research on December 21, 2023.
